TNNI2 (DA2B1), A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Disorders

Target Name: TNNI2

NCBI ID: G7136

TNNI2

TNNI2 (DA2B1), A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Disorders

Neurodegenerative disorders (NDs) are a group of progressive diseases that affect the nervous system and can cause a range of motor, cognitive, and behavioral symptoms. These disorders are often irreversible, and current treatment options are limited in their effectiveness. Therefore, the development of new treatments and biomarkers is crucial for the improvement of patient outcomes.

TNNI2 (Tissue Noxin Interface 2) is a protein that is expressed in various tissues, including brain, heart, and kidneys. It is a key regulator of the cellular response to environmental stress, including oxidative stress. TNNI2 plays a crucial role in the detoxification of xenobiotics, such as those that are generated by cellular metabolism, by activating the detoxification enzymes NADPH quinone oxidoreductase (NQOR) and superoxide dismutase (SDH).

DA2B1, also known as Nicotinamide mononucleotide (NMN), is a compound that has been shown to have neuroprotective properties in various experimental models of neurodegenerative disorders. DA2B1 has been shown to protect against neurotoxins, such as glutamate, by modulating the activity of cellular stress response pathways.

The Interaction between TNNI2 and DA2B1

The interaction between TNNI2 and DA2B1 has been shown to play a crucial role in the regulation of cellular stress response and the detoxification of xenobiotics. TNNI2 activation of NQOR and SDH generates reactive oxygen species (ROS) that can damage cellular components and contribute to the development of neurodegenerative disorders.

In contrast, DA2B1 has been shown to modulate the activity of NQOR and SDH by inhibiting the production of ROS. This modulation of cellular stress response pathways by DA2B1 provides a potential mechanism for its neuroprotective properties.

The Potential Role of TNNI2 and DA2B1 in Neurodegenerative Disorders

The accumulation of ROS in neurodegenerative disorders is thought to contribute to the development and progression of these disorders. Therefore, modulation of TNNI2 and DA2B1 activity may provide a new approach to the treatment of neurodegenerative disorders.

TNNI2 has been shown to play a negative role in the development of neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). TNNI2 overexpression has been shown to increase the production of ROS and contribute to the development of neurodegeneration.

On the other hand, DA2B1 has been shown to have neuroprotective properties in various neurodegenerative disorders. DA2B1-mediated neuroprotection may be due to its ability to modulate the activity of stress response pathways, thereby reducing the production of ROS and protecting cellular components.

Potential Therapeutic Strategies for TNNI2 and DA2B1 Modulation

Given the potential role of TNNI2 and DA2B1 in the development and progression of neurodegenerative disorders, there is a growing interest in developing therapeutic strategies that target these molecules.

One potential approach to treating neurodegenerative disorders is to inhibit TNNI2 activity and enhance DA2B1 activity. This can be achieved by small molecules, such as those that modulate the activity of NQOR and SDH, or by using antibodies that specifically target TNNI2 and enhance DA2B1 expression.

Another potential approach is to modulate the activity of TNNI2 and DA2B1 in a more targeted manner. For example,

Protein Name: Troponin I2, Fast Skeletal Type

Functions: Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity

The "TNNI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNNI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets